Amag Pharmaceuticals Inc., of Waltham, Mass., reported that total revenues for the fourth quarter ended Dec. 31, 2014, were 145 percent greater than for the same period in 2013, driven by increased sales of Feraheme (ferumoxytol) Injection and the addition of Makena (hydroxyprogesterone caproate injection) sales following the closing of the acquisition of Lumara Health in November.